Genotype of Varicella-Zoster virus isolates in South Korea

Journal of Clinical Microbiology

Volumn 49, Issue 5, 2011, Pages 1913-1916

  Kim, Kye Hyung ^a,c   Choi, Young Ju ^b   Song, Kyoung Ho ^a   Park, Wan Beom ^a   Jeon, Jae Hyun ^a,d   Park, Sang Won ^a   Kim, Hong Bin ^a   Kim, Nam Joong ^a   Oh, Myoung Don ^a  

^a Seoul National University College of Medicine   (South Korea)

^b National Cancer Center   (South Korea)

^c Pusan National University School of Medicine   (South Korea)

^d Dongnam Institute of Radiological and Medical Science   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

RESTRICTION ENDONUCLEASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHICKENPOX; CHILD; CONTROLLED STUDY; DNA POLYMORPHISM; DNA PURIFICATION; FEMALE; GENOTYPE; HERPES ZOSTER; HUMAN; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PHYLOGENY; PRESCHOOL CHILD; PRIORITY JOURNAL; RESTRICTION MAPPING; SCHOOL CHILD; SEQUENCE ANALYSIS; SOUTH KOREA; VARICELLA ZOSTER VIRUS; VIRUS ISOLATION; VIRUS STRAIN;

ADOLESCENT; ADULT; AGED; CHICKENPOX; CHILD; CLUSTER ANALYSIS; DNA, VIRAL; FEMALE; GENOTYPE; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; MALE; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; MOLECULAR SEQUENCE DATA; REPUBLIC OF KOREA; SEQUENCE ANALYSIS, DNA; VIRAL PROTEINS; YOUNG ADULT;

HERPES ZOSTER; HUMAN HERPESVIRUS 3;

EID: 79955536241     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02356-10     Document Type: Article

References (25)

1. Centers for Disease Control and Prevention. 1999. Prevention of varicella. Update recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommend. Rep. 48:1-5.
2. Centers for Disease Control and Prevention. 1996. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommend. Rep. 45:1-36.
3. Choi, E. H. 2008. Varicella vaccine. Hanyang Med. Rev. 28:30-36.
4. Choi, Y. J., K. H. Kim, and M.-d. Oh. 2010. Genotype of varicella zoster virus isolated from Korean elderly patients with herpes zoster. Infect. Chemother. 42:162-170.
5. Davison, A. J., and J. E. Scott. 1986. The complete DNA sequence of varicella-zoster virus. J. Gen. Virol. 67:1759-1816.
6. Dumas, A. M., J. D. Andrew, J. L. M. C. Geelen, W. Maris, and J. V. D. Noordaa. 1980. Infectivity and molecular weight of varicella-zoster virus DNA. J. Gen. Virol. 47:233-235.
7. GlaxoSmithKline. 2010. Varilrix package leaflet: information for the user. GlaxoSmithKline, Rixensart, Belgium.
8. Gnann, J. W., and J. R. J. Whitley. 2002. Herpes zoster. N. Engl. J. Med. 347:340-346.
9. Green Cross Company. 2010. Suduvax package insert. Green Cross Company, Yongin, South Korea.
10. Hawrami, K., et al. 1997. Molecular epidemiology of varicella-zoster virus in East London, England, between 1971 and 1995. J. Clin. Microbiol. 35:2807-2809. (Pubitemid 27452414)
11. LaRussa, P., et al. 1992. Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates. J. Virol. 66:1016-1020.
12. Liu, J., M. Wang, L. Gan, S. Yang, and J. Chen. 2009. Genotyping of clinical varicella-zoster virus isolates collected in China. J. Clin. Microbiol. 47:1418-1423.
13. Loparev, V. N., T. Argaw, P. R. Krause, M. Takayama, and D. S. Schmid. 2000. Improved identification and differentiation of varicella-zoster virus (VZV) wild-type strains and an attenuated varicella vaccine strain using a VZV open reading frame 62-based PCR. J. Clin. Microbiol. 38:3156-3160.
14. Loparev, V. N., et al. 2004. Global identification of three major genotypes of varicella-zoster virus: longitudinal clustering and strategies for genotyping. J. Virol. 78:8349-8358. (Pubitemid 38944319)
15. Loparev, V. N., et al. 2007. Identification of five major and two minor genotypes of varicella-zoster virus strains: a practical two-amplicon approach used to genotype clinical isolates in Australia and New Zealand. J. Virol. 81:12758-12765. (Pubitemid 350156913)
16. Merck and Co., Inc. 2010. Varivax prescribing information. Merck and Co., Inc., Whitehouse Station, NJ.
17. Nguyen, H. Q., A. O. Jumaan, and J. F. Seward. 2005. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N. Engl. J. Med. 352:450-458.
18. Roush, S. W., L. McIntyre, and L. M. Baldy (ed.). 2008. Manual for the surveillance of vaccine-preventable diseases, 4th ed. Centers for Disease Control and Prevention, Atlanta, GA.
19. Sadzot-Delvaux, C., et al. 2008. Varicella vaccination in Japan, South Korea, and Europe. J. Infect. Dis. 197(Suppl. 2):S185-S190.
20. Sauerbrei, A., et al. 2003. Molecular characterisation of varicella-zoster virus strains in Germany and differentiation from the Oka vaccine strain. J. Med. Virol. 71:313-319.
21. Sauerbrei, A., and P. Wutzler. 2007. Different genotype pattern of varicella-zoster virus obtained from patients with varicella and zoster in Germany. J. Med. Virol. 79:1025-1031.
22. Sergeev, N., E. Rubtcova, V. Chizikov, D. S. Schmid, and V. N. Loparev. 2006. New mosaic subgenotype of varicella-zoster virus in the U. S. A.: VZV detection and genotyping by oligonucleotide-microarray. J. Virol. Methods 136:8-16.
23. Seward, J. F., et al. 2002. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA 287:606-611. (Pubitemid 34252012)
24. Takahashi, M., et al. 2008. Development of varicella vaccine. J. Infect. Dis. 197:S41-S44.
25. Takahashi, M., et al. 1974. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet ii:1288-1290.